Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting.
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
pubmed:
27
12
2018
medline:
3
2
2021
entrez:
27
12
2018
Statut:
ppublish
Résumé
The criterion standard for anti-topoisomerase I antibody (anti-topo I antibody) testing in systemic sclerosis (SSc) uses immunodiffusion (ID) techniques, but enzyme-linked immunosorbent assay (ELISA) and multiple-bead technology are often used in current settings to save time and cost. Our aim was to assess the performance of the multiple-bead assay, ELISA, and ID testing methods. We conducted a retrospective study of patients at the University of Michigan whose extractable nuclear antigen 10 autoantibody panel tested positive for the anti-topo I antibody by multiple-bead technology during a 1-year period. All samples positive by multiple-bead assay were sent to the RDL Laboratories and reflexed for ELISA, and all anti-topo I antibodies positive by ELISA were further tested by ID. Clinical data were reviewed by a rheumatologist and assessed for presence of SSc. Data were analyzed via frequency tables. Approximately 9500 extractable nuclear antigen 10 panels were ordered by physicians at the University of Michigan. Of these, 129 patients were positive for the anti-topo I antibody by multiple-bead assay, 51 were positive by multiple-bead assay and ELISA, and 21 were positive by multiple-bead assay, ELISA, and ID. We found that 26.4% of patients positive by multiple-bead assay, 47.1% positive by multiple-bead assay and ELISA, and 95.2% positive by multiple-bead assay, ELISA, and ID had SSc. Multiple-bead assays have a high rate of false-positive results for the anti-topo I antibody in patients without clinical evidence of SSc. A stepwise approach of confirmation of positive multiple-bead assay results using both ELISA and ID improves the predictive value of antibody testing for the diagnosis of SSc.
Sections du résumé
BACKGROUND/OBJECTIVE
OBJECTIVE
The criterion standard for anti-topoisomerase I antibody (anti-topo I antibody) testing in systemic sclerosis (SSc) uses immunodiffusion (ID) techniques, but enzyme-linked immunosorbent assay (ELISA) and multiple-bead technology are often used in current settings to save time and cost. Our aim was to assess the performance of the multiple-bead assay, ELISA, and ID testing methods.
METHODS
METHODS
We conducted a retrospective study of patients at the University of Michigan whose extractable nuclear antigen 10 autoantibody panel tested positive for the anti-topo I antibody by multiple-bead technology during a 1-year period. All samples positive by multiple-bead assay were sent to the RDL Laboratories and reflexed for ELISA, and all anti-topo I antibodies positive by ELISA were further tested by ID. Clinical data were reviewed by a rheumatologist and assessed for presence of SSc. Data were analyzed via frequency tables.
RESULTS
RESULTS
Approximately 9500 extractable nuclear antigen 10 panels were ordered by physicians at the University of Michigan. Of these, 129 patients were positive for the anti-topo I antibody by multiple-bead assay, 51 were positive by multiple-bead assay and ELISA, and 21 were positive by multiple-bead assay, ELISA, and ID. We found that 26.4% of patients positive by multiple-bead assay, 47.1% positive by multiple-bead assay and ELISA, and 95.2% positive by multiple-bead assay, ELISA, and ID had SSc.
CONCLUSIONS
CONCLUSIONS
Multiple-bead assays have a high rate of false-positive results for the anti-topo I antibody in patients without clinical evidence of SSc. A stepwise approach of confirmation of positive multiple-bead assay results using both ELISA and ID improves the predictive value of antibody testing for the diagnosis of SSc.
Identifiants
pubmed: 30585996
doi: 10.1097/RHU.0000000000000971
pmc: PMC6586532
mid: NIHMS1508611
pii: 00124743-202004000-00007
doi:
Substances chimiques
Antibodies, Antinuclear
0
Autoantibodies
0
DNA Topoisomerases, Type I
EC 5.99.1.2
TOP1 protein, human
EC 5.99.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-118Subventions
Organisme : NIAMS NIH HHS
ID : K24 AR063120
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR070470
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR007080
Pays : United States
Références
Clin Immunol Immunopathol. 1990 Dec;57(3):399-410
pubmed: 2173985
Clin Diagn Lab Immunol. 2004 Nov;11(6):1054-9
pubmed: 15539505
Am J Med. 1997 Sep;103(3):242-8
pubmed: 9316557
Arthritis Rheum. 1988 Feb;31(2):196-203
pubmed: 3348823
Ann N Y Acad Sci. 2005 Jun;1050:327-39
pubmed: 16014549
Rheumatology (Oxford). 2001 Oct;40(10):1135-40
pubmed: 11600743
Arthritis Rheum. 2003 Jun 15;49(3):399-412
pubmed: 12794797
J Immunol Methods. 2010 Jun 30;358(1-2):75-80
pubmed: 20438730
Arthritis Rheum. 2001 Feb;44(2):376-83
pubmed: 11229469
Ann Rheum Dis. 2004 Sep;63(9):1155-8
pubmed: 15308527
Anal Bioanal Chem. 2007 Jun;388(3):613-8
pubmed: 17404717
Arthritis Rheum. 2007 Aug;56(8):2740-6
pubmed: 17665460
Front Immunol. 2015 Apr 21;6:181
pubmed: 25954274
Autoimmunity. 2005 Feb;38(1):65-72
pubmed: 15804707
Arthritis Res Ther. 2009;11(1):R28
pubmed: 19232127
J Rheumatol. 1990 Oct;17(10):1314-9
pubmed: 2174971
Autoimmun Rev. 2010 Sep;9(11):756-60
pubmed: 20601198
Rheum Dis Clin North Am. 2003 May;29(2):239-54
pubmed: 12841293
Arthritis Res Ther. 2003;5(2):80-93
pubmed: 12718748
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Medicine (Baltimore). 2010 Jan;89(1):62-67
pubmed: 20075706
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Clin Dev Immunol. 2005 Jun;12(2):107-11
pubmed: 16050141